Vertex Pharmaceuticals Incorporated (VRTX) Position Increased by Royal Bank of Canada
Royal Bank of Canada increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 67.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 141,971 shares of the pharmaceutical company’s stock after purchasing an additional 57,178 shares during the quarter. Royal Bank of Canada owned approximately 0.06% of Vertex Pharmaceuticals worth $18,295,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. AHL Partners LLP bought a new stake in shares of Vertex Pharmaceuticals in the second quarter worth about $916,000. Sun Life Financial INC grew its stake in shares of Vertex Pharmaceuticals by 14,883.3% in the second quarter. Sun Life Financial INC now owns 1,798 shares of the pharmaceutical company’s stock worth $232,000 after purchasing an additional 1,786 shares during the last quarter. Institute for Wealth Management LLC. bought a new stake in shares of Vertex Pharmaceuticals in the second quarter worth about $694,000. Employees Retirement System of Texas grew its stake in shares of Vertex Pharmaceuticals by 83.6% in the second quarter. Employees Retirement System of Texas now owns 123,000 shares of the pharmaceutical company’s stock worth $15,851,000 after purchasing an additional 56,000 shares during the last quarter. Finally, HighTower Advisors LLC grew its stake in shares of Vertex Pharmaceuticals by 3.2% in the second quarter. HighTower Advisors LLC now owns 18,975 shares of the pharmaceutical company’s stock worth $2,447,000 after purchasing an additional 588 shares during the last quarter. 92.85% of the stock is currently owned by institutional investors.
In other Vertex Pharmaceuticals news, SVP Paul M. Silva sold 43,443 shares of the business’s stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $161.07, for a total value of $6,997,364.01. Following the transaction, the senior vice president now directly owns 26,516 shares in the company, valued at approximately $4,270,932.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Jeffrey Chodakewitz sold 3,437 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $151.64, for a total transaction of $521,186.68. The disclosure for this sale can be found here. Insiders have sold 518,357 shares of company stock worth $83,154,633 over the last 90 days. 1.80% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) Position Increased by Royal Bank of Canada” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/10/12/vertex-pharmaceuticals-incorporated-vrtx-position-increased-by-royal-bank-of-canada.html.
Shares of Vertex Pharmaceuticals Incorporated (VRTX) opened at 154.02 on Thursday. Vertex Pharmaceuticals Incorporated has a 12 month low of $71.46 and a 12 month high of $167.85. The stock has a market capitalization of $38.83 billion, a PE ratio of 147.95 and a beta of 1.73. The stock’s 50 day moving average is $154.29 and its 200 day moving average is $135.25.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.33. The firm had revenue of $544.10 million for the quarter, compared to analyst estimates of $489.95 million. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. Vertex Pharmaceuticals’s quarterly revenue was up 26.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.24 earnings per share. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.62 earnings per share for the current fiscal year.
Several research firms recently issued reports on VRTX. DA Davidson assumed coverage on Vertex Pharmaceuticals in a research note on Friday, September 29th. They issued a “buy” rating and a $200.00 target price on the stock. BTIG Research assumed coverage on Vertex Pharmaceuticals in a research report on Friday, September 29th. They set a “buy” rating and a $200.00 price objective on the stock. BMO Capital Markets reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, September 27th. Zacks Investment Research raised Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $174.00 price objective on the stock in a research report on Tuesday, September 26th. Finally, Vetr cut Vertex Pharmaceuticals to a “sell” rating in a research report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, twenty-three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $167.04.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.